Trials (Oct 2022)

Personalized Disease Prevention (PDP): study protocol for a cluster-randomized clinical trial

  • Glen B. Taksler,
  • Phuc Le,
  • Bo Hu,
  • Jay Alberts,
  • Allen J. Flynn,
  • Michael B. Rothberg

DOI
https://doi.org/10.1186/s13063-022-06750-7
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background The US Preventive Services Task Force recommends 25 primary preventive services for middle-aged adults, but it can be difficult to do them all. Methods The Personalized Disease Prevention (PDP) cluster-randomized clinical trial will evaluate whether patients and their providers benefit from an evidence-based decision tool to prioritize preventive services based on their potential to improve quality-adjusted life expectancy. The decision tool will be individualized for patient risk factors and available in the electronic health record. This Phase III trial seeks to enroll 60 primary care providers (clusters) and 600 patients aged 40–75 years. Half of providers will be assigned to an intervention to utilize the decision tool with approximately 10 patients each, and half will be assigned to usual care. Mixed-methods follow-up will include collection of preventive care utilization from electronic health records, patient and physician surveys, and qualitative interviews. We hypothesize that quality-adjusted life expectancy will increase by more in patients who receive the intervention, as compared with controls. Discussion PDP will test a novel, holistic approach to help patients and providers prioritize the delivery of preventive services, based on patient risk factors in the electronic health record. Trial registration ClinicalTrials.gov NCT05463887. Registered on July 19, 2022.

Keywords